CBP inhibitor 1 is primarily used in epigenetic research to modulate histone acetylation. It selectively inhibits the histone acetyltransferase (HAT) activity of CREB-binding protein (CBP), which plays a key role in gene expression regulation. This compound is valuable in studying cellular processes such as differentiation, proliferation, and apoptosis, particularly in cancer models where dysregulated acetylation contributes to tumor growth. It has been employed in preclinical studies to investigate its potential in treating hematological malignancies and solid tumors by reactivating tumor suppressor genes. Additionally, CBP inhibitor 1 is used to probe the role of CBP in inflammatory pathways and neurodegenerative diseases, offering insights into novel therapeutic strategies targeting epigenetic mechanisms.